Pacific Biosciences of California, Inc. reported $82M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $82M (to Q3 2020). Net income: −$131M, trailing twelve months to Q2 2026. Free cash flow: −$124M, trailing twelve months to Q2 2026. EPS: −$0.43, trailing twelve months to Q2 2026.

PACBPacific Biosciences of California, Inc.

Healthcare

$2.30+64% 1Y

$2.30

$1.1152 weeks$2.88

PACB as reported

Pacific Biosciences of California, Inc. reported $82M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.

$82M

Revenue, trailing twelve months · to Q3 2020 · every figure below is as filed, with no scoring applied

Net income: −$131M
Net income · −75% year on year · trailing twelve months to Q2 2026
Free cash flow: −$124M
Free cash flow · −20% year on year · trailing twelve months to Q2 2026
EPS: −$0.43
EPS · −81% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PACB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$82M	n/a	Q3 2020 · 23 quarters behind
Net income	−$131M	−75%	Q2 2026
EPS	−$0.43	−81%	Q2 2026
Gross margin	41%	n/a	Q3 2020 · 23 quarters behind
Operating margin	−131%	n/a	Q3 2020 · 23 quarters behind
Net margin	−59%	n/a	Q3 2020 · 23 quarters behind
ROE	−4162%	n/a	Q2 2026
ROA	−42%	n/a	Q2 2026
ROIC	−34%	n/a	Q1 2023 · 13 quarters behind
Free cash flow	−$124M	−20%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.